CD4 and neoplasm: In addition, another study found that atropine and muscarinic receptor 3 blockers reduced tumor weight, volume, and enhanced antitumor immune responses by increasing infiltration of CD4+ and CD8+ T cells and significantly reducing PD-L1 expression in a CRC mouse model (Kuol et al., 2022).